Iovance Biotherapeutics has been granted a patent for an improved method of expanding tumor infiltrating lymphocytes (TILs) for cancer treatment. The closed system process enhances efficacy, phenotype, and metabolic health of TILs in a shorter time, reducing costs and contamination risks. GlobalData’s report on Iovance Biotherapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Iovance Biotherapeutics, Cytokine activate T-cell based compositions was a key innovation area identified from patents. Iovance Biotherapeutics's grant share as of May 2024 was 9%. Grant share is based on the ratio of number of grants to total number of patents.
Method for expanding and administering tumor infiltrating lymphocytes
A recently granted patent (Publication Number: US11998568B2) outlines a method for treating cancer by administering expanded tumor infiltrating lymphocytes (TILs) to a subject. The method involves a multi-step process, including the expansion of TIL populations in closed containers, supplementation with specific factors like IL-2 and antigen presenting cells (APCs), and cryopreservation of the harvested TIL population for later administration to the subject. The therapeutic dosage of TILs administered is crucial for effective treatment, ranging from 1×109 to 5×1010 TILs, depending on the specific requirements of the patient.
Furthermore, the patent details additional steps such as the use of a non-myeloablative lymphodepletion regimen before TIL administration, treatment with high-dose IL-2 post-TIL infusion, and specific ratios for supplementing TILs with PBMCs. The method is applicable to various types of cancer, including melanoma, ovarian cancer, lung cancer, and head and neck cancer, among others. The timeline for the entire process, from TIL expansion to administration, ranges from about 10 to 22 days, ensuring a timely and efficient treatment protocol. The use of gas-permeable bags for containment during TIL expansion highlights the importance of maintaining a controlled environment throughout the procedure, contributing to the overall success of the treatment method.
To know more about GlobalData’s detailed insights on Iovance Biotherapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
